Skin neoplasm

This study aimed to find a safe dose of a custom-made mRNA vaccine for people with a rare skin cancer called cutaneous angiosarcoma. The vaccine was designed to train the immune system to attack the cancer. However, the trial was withdrawn before any participants were enrolled.

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…

This phase II trial tests pembrolizumab, an immunotherapy drug, in 57 patients with desmoplastic melanoma, a rare skin cancer. The drug helps the immune system attack cancer cells. The study includes patients whose tumors can be surgically removed (cohort A) and those whose canno…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tests two injected medications, bleomycin and pingyangmycin, for treating plantar warts. Each of the 200 adult participants will receive both drugs on different warts to compare which works better. The main goal is complete clearing of the warts, with follow-up for 36 …

This study tests whether the drug afatinib can shrink tumors in people with advanced cutaneous squamous cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. About 25 adults with adequate organ function will receive afatinib, and researchers wil…

This phase 3 trial tests whether the immunotherapy drug ipilimumab is better than high-dose interferon alfa-2b at preventing melanoma from coming back in patients whose cancer was removed by surgery. Over 1,600 people with high-risk stage III or IV melanoma took part. The study m…

This phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…

This phase III trial compares two sequences of treatment for advanced melanoma with a BRAF mutation. One group starts with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if needed; the other group starts with targeted therapy the…

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This phase II trial tests whether adding a growth factor (GM-CSF) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be surgically removed are randomly assigned to get ipilimumab alone…

This study tests whether adding a drug called sargramostim to the standard immunotherapy combination of nivolumab and ipilimumab helps people with advanced melanoma live longer. About 600 patients with stage III or IV melanoma that cannot be surgically removed are participating. …

This phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …

This phase 2 trial tests whether adding tuvusertib (a drug that blocks a DNA repair enzyme) to avelumab (an immunotherapy) can slow cancer growth in people with advanced Merkel cell cancer that didn't respond to prior treatment. About 50 participants will receive either the combi…

This phase II trial studies whether giving the immunotherapy drug pembrolizumab both before and after surgery is more effective than giving it only after surgery for patients with stage III-IV high-risk melanoma. About 313 participants will be randomly assigned to one of two trea…

This phase 2 trial compares two ways of taking the targeted drugs dabrafenib and trametinib for advanced BRAF-mutant melanoma: continuously versus with planned breaks. About 280 people with stage III or IV melanoma that cannot be surgically removed are participating. The goal is …

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This trial investigates whether adding metformin, a common diabetes drug, to the immunotherapy pembrolizumab (Keytruda) can improve treatment for people with advanced melanoma. The study focuses on reversing metabolic problems inside tumors that may weaken immune cells. Participa…

This trial investigates whether combining atezolizumab (a drug that boosts the immune system) with bevacizumab (a drug that blocks blood vessel growth) can shrink tumors in people with advanced melanoma that cannot be removed by surgery or has spread. The study focuses on patient…

This early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This early-phase trial tests whether injecting special immune cells (natural killer cells) directly into skin cancer tumors can safely kill cancer cells. The study compares two types of donor NK cells—standard ones and ones engineered to be more potent—in 40 patients with basal o…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study was designed to test a drug called tolododekin alfa (ANK-101) given before surgery to kidney transplant recipients with high-risk skin cancer. The goal was to see if the drug could reduce the number of cancer cells in the removed tissue. However, the trial was withdraw…

This phase 3 trial is testing whether the immunotherapy drug nivolumab (Opdivo) can prevent melanoma from coming back in people who have had their stage IIB/C melanoma completely removed. About 790 adults and children are randomly assigned to receive either nivolumab or a placebo…

This study looks at whether active surveillance (watching the cancer without treating it right away) is a safe and comfortable choice for people aged 65 and older who have a low-risk type of skin cancer called basal cell carcinoma. The cancer is slow-growing and unlikely to sprea…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This Phase II study tested a combination of two drugs—peginterferon alfa-2b and temozolomide—in 29 children with high-risk melanoma that had spread or come back. The main goal was to see how well the tumors shrank and to check for side effects. The study also looked at how long c…

This early-stage trial tests a combination of two drugs, duvelisib and nivolumab, in 38 adults with advanced mycosis fungoides or Sezary syndrome (types of skin lymphoma). The goal is to find the safest dose and see if the drugs can shrink tumors. Duvelisib blocks certain enzymes…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This Phase 2 trial tests whether combining bevacizumab (Avastin) with atezolizumab (Tecentriq), with or without cobimetinib (Cotellic), can shrink or control melanoma that has spread to the brain. The study enrolls 29 adults with untreated brain metastases who are not taking ster…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This study tests whether combining an experimental drug (GSK2636771) with the immunotherapy pembrolizumab (Keytruda) can help control metastatic melanoma in patients whose tumors have lost a protein called PTEN. The trial involves up to 41 adults with advanced melanoma that hasn'…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This phase II trial tests whether a combination of amivantamab and hyaluronidase works as well as cetuximab for treating skin squamous cell carcinoma that has come back or spread. The study enrolls 86 immunocompromised participants, including organ transplant recipients. The goal…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This study tests a combination of three drugs—dabrafenib, trametinib, and navitoclax—in people with BRAF mutant melanoma or other solid tumors that have spread or can't be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 adu…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This phase 3 trial tests whether the immunotherapy drug avelumab can keep Merkel cell carcinoma from returning in patients whose cancer has spread to lymph nodes and who have already had surgery or radiation. About 100 adults will receive either avelumab or a placebo every two we…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests a new type of radiation therapy, called DaRT, for people with recurrent squamous cell skin cancer that has not responded to standard treatments. About 86 participants will receive the treatment directly into their tumors. The main goals are to see if the tumors s…

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This study tests whether infliximab, a drug used for inflammatory conditions, can treat colitis (colon inflammation) caused by immune checkpoint inhibitors in people with stage III or IV skin cancer. About 42 participants will receive either infliximab or steroids, and researcher…

This early-phase trial tests two drugs, mogamulizumab and brentuximab vedotin, given together to people with a rare type of skin lymphoma (CTCL or mycosis fungoides) that has not responded to prior treatment. The main goal is to see if the combination is safe and to find the best…

This study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…

This phase II trial is testing two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or cannot be removed by surgery. One group receives nivolumab (immunotherapy) plus dabrafenib and trametinib (targeted therapy); the other receives n…

This early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This phase 2 trial is testing whether giving immunotherapy drugs (cemiplimab alone or with fianlimab) before surgery can shrink advanced basal cell carcinoma of the head and neck. The goal is to make surgery less extensive, preserving important structures like the eye, nose, or l…

This study tests whether combining pembrolizumab (an immunotherapy) with gemcitabine (a chemotherapy drug) can shrink tumors in people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The trial enrolled 14 adults who had already tried at least one …

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This early-phase trial is testing whether taking high-dose vitamin B5 (pantothenic acid) can help standard immunotherapy work better for people with advanced melanoma that cannot be surgically removed. The study includes 12 participants who have not had prior treatment for their …

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This study tests whether adding cetuximab to avelumab helps control advanced skin squamous cell carcinoma better than avelumab alone. About 60 adults with cancer that has spread will receive one of the two treatments. The goal is to see if the combination slows cancer growth and …

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This phase II trial tests whether adding the immunotherapy drug nivolumab to the chemotherapy paclitaxel helps shrink tumors in people with angiosarcoma who haven't had taxane drugs before. For those who have already received taxanes, the trial tests a combination of nivolumab an…

This phase III trial tests whether the immunotherapy drug pembrolizumab can prevent Merkel cell cancer from returning after it has been surgically removed. About 280 adults with stage I-III Merkel cell cancer are randomly assigned to receive either pembrolizumab or standard obser…

This trial tests a new way of taking the drug sonidegib for people with advanced basal cell carcinoma that cannot be surgically removed. Instead of taking the drug continuously, patients who have already achieved a complete response will take it in cycles with breaks (14 days on/…

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This phase II trial tests whether giving the immunotherapy drug cemiplimab before surgery can shrink high-risk skin cancers that have not spread far. The study enrolls 35 people with resectable squamous cell carcinoma. Participants receive cemiplimab intravenously, then undergo s…

This phase II trial is testing the drug dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. Researchers are looking at side effects and whether it helps patients live longer or slows tumor growth.

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This study compares a new biosimilar drug (GME751) to the standard immunotherapy Keytruda in 322 adults with stage II or III melanoma that has been surgically removed. The goal is to see if the biosimilar stays in the body and works as well as Keytruda in preventing the cancer fr…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…

This study tests a gel (Ameluz®) plus red light therapy for actinic keratosis, rough precancerous patches on skin. It includes 172 adults with 4-15 spots on arms, legs, neck, or trunk. The goal is to see if the treatment clears these spots better than a placebo gel.

This early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, …

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This phase 2 trial studies a combination of two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab—in 43 adults with advanced melanoma that has worsened despite prior anti-PD1/L1 therapy. T-VEC is a modified virus that infects and kills cancer cells while also…

This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help …

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This study was designed to test a new drug called Resimmune against an oral medication (Zolinza) for people with a type of skin lymphoma called mycosis fungoides. The goal was to see if a single four-day treatment could completely clear skin lesions. However, the trial was withdr…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…

This phase 2 trial is testing whether combining radiation therapy with the immunotherapy drug cemiplimab can effectively treat locally advanced skin cancer that cannot be surgically removed. The study involves 34 participants who will receive both treatments over about 12 months.…

This early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This pilot study tested whether adding low-dose radiation (brachytherapy) to standard immunotherapy could help shrink tumors in people with advanced melanoma, kidney cancer, or urothelial cancer. Only 5 participants were enrolled, and the main goal was to see how many responded t…

This early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…

This early-phase trial is testing whether adding an experimental drug called VX15/2503 to standard immunotherapies (ipilimumab or nivolumab) can help treat stage IIIB-D melanoma that can be removed by surgery. About 41 participants will receive the drug combination before surgery…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This phase 2 trial is testing the drug ibrutinib in 18 people with stage IV melanoma that has not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The study aims to see if the drug can shrink tumors and how long it keeps t…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This phase II trial is testing whether a combination of two drugs, rigosertib and pembrolizumab, can help people with advanced melanoma that no longer responds to standard immunotherapy. The study involves 7 participants with unresectable or metastatic melanoma. The goal is to se…

This early-phase study tests an experimental drug called DS-3201b in about 100 adults with non-Hodgkin lymphoma whose cancer has come back or is not responding to current treatments. The main goals are to find a safe dose and see how the drug works in the body. The study also che…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study planned to test whether adding surgery, radiation, or electrochemotherapy could help control melanoma tumors that did not shrink with encorafenib + binimetinib combination therapy. It was designed for adults with BRAF-mutated melanoma who had been on the drugs for at l…

This study looks at whether a very low dose of radiation (4 Gy) can effectively control a rare, slow-growing type of skin lymphoma called primary indolent cutaneous B-cell lymphoma. Researchers will review records from 52 patients who received this low-dose treatment to see how l…

This study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…

This phase II trial tests two drugs, pembrolizumab and lenvatinib, given before surgery to people with stage III melanoma that can be removed. The goal is to see if the combination can shrink or eliminate the tumor before the operation. Twenty-one participants will receive the dr…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This study tests an experimental therapy called lifileucel for people with advanced melanoma that has spread or cannot be removed by surgery and has worsened after standard treatments. About 100 adults will receive their own tumor-fighting immune cells (TILs) grown in a lab. The …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This early-phase study tests a new oral drug called GS-9911, alone or with an intravenous immunotherapy (zimberelimab), in 45 adults with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the best dose, and see how the body handl…

This study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including ovarian, endometrial, breast, and others) that have specific genetic changes or have stopped responding to similar treatments. The first phase finds…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-phase trial tests whether giving patients with advanced melanoma immune cells that have been genetically modified to resist tumor-suppressing signals can help fight the cancer. The modified T-cells are given along with high-dose Interleukin-2, a drug that boosts immune…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This early-phase trial tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the two chemotherapy drugs when …

This study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study is testing whether a precise form of radiation called proton therapy can control head and neck cancer after surgery as well as standard X-ray radiation, but with fewer side effects. About 174 adults with newly diagnosed head and neck cancer will receive either proton t…

This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…

This phase 2 trial is testing whether giving a combination of two drugs—lenvatinib and pembrolizumab—before surgery can help people with Merkel cell carcinoma. The study involves 26 participants with stage II, III, or IV disease. The main goal is to see if the treatment leads to …

This study tests a combination of targeted radiation (CART) and the immunotherapy drug avelumab in 18 people with advanced Merkel cell carcinoma that has spread or cannot be removed by surgery. The goal is to see if this approach can slow or stop the cancer from growing. Particip…

This phase 2 trial is testing whether giving two immunotherapy drugs, nivolumab and ipilimumab, before surgery can shrink stage III melanoma tumors and prevent the cancer from returning. The 28 participants will also receive an experimental PET scan that images immune cells to se…

This early-phase trial tests whether combining the immunotherapy pembrolizumab (Keytruda) with chemotherapy drugs pralatrexate and decitabine is safe and can shrink tumors in people with relapsed peripheral or cutaneous T-cell lymphoma. About 37 adults whose cancer has returned o…

This study is testing a device called DaRT that delivers alpha radiation directly into tumors. It is for people with skin cancer, mouth tumors, or superficial soft tissue sarcoma who have not responded to other treatments or cannot have standard therapy. The goal is to see if the…

This study tests three ways emergency responders help children breathe: a bag-mask, a throat tube, or a breathing tube. It includes 3,000 children under 18 with cardiac arrest, severe injury, or breathing failure. The goal is to see which method leads to more days alive and out o…

This study tests whether adding two targeted pills (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a BRAF gene mutation. About 257 adults with untreated, advanced or spreading…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 a…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, in 8 adults with melanoma that stopped responding to PD-1 inhibitors. The goal is to see if the combination can shrink tumors or stop them from growing. The study is active but …

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This early-stage trial tests a new drug called BAY2965501, which boosts the immune system to fight cancer. It is given alone or with other drugs like pembrolizumab and chemotherapy. The study includes about 284 people with advanced solid tumors (skin, kidney, stomach, or lung can…

This study compares a new type of radiation called FLASH, which delivers the dose in less than a second, to standard radiation for treating two common skin cancers: basal cell carcinoma and squamous cell carcinoma. About 60 patients aged 60 and older who cannot have surgery will …

This study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…

This Phase 3 trial tests whether adding the drug cemiplimab (Libtayo) after surgery and radiation helps prevent high-risk cutaneous squamous cell carcinoma from returning. About 415 participants receive either cemiplimab or a placebo intravenously every 3 weeks. The study compare…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This study tests whether a laser, guided by a special camera (OCT), can effectively treat basal cell carcinoma, a common skin cancer. About 40 adults with confirmed BCC will receive the laser treatment. The goal is to see if the cancer is completely removed, potentially offering …

This early-phase trial tests a personalized vaccine called NeoVax, combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab), in 10 people with advanced melanoma. The goal is to see if the combination is safe and helps the immune syst…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial includes 37 adults and aims to find t…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This phase 2 trial is testing several combinations of experimental drugs (LXH254, LTT462, trametinib, ribociclib) in 134 people with advanced melanoma that has a BRAF or NRAS mutation and has stopped responding to prior treatment. The main goal is to see if these combinations can…

This study tests whether adding focused radiation to a two-drug immunotherapy combination works better than the drugs alone for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. About 50 adults with cancer that has spread or cannot be removed will rec…

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This early-phase trial is testing whether the immunotherapy drug atezolizumab (Tecentriq) is safe to use before surgery in people with high-risk melanoma that hasn't spread. The study includes 20 participants and focuses on whether the treatment causes side effects that delay the…

This early-phase trial tests a combination of three drugs (dasatinib, temsirolimus, and cyclophosphamide) in children and young adults with advanced solid tumors that have come back or not responded to standard treatment. The main goals are to find the safest dose and understand …

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study tested whether giving the immunotherapy drug pembrolizumab after surgery helps prevent melanoma from returning in people with high-risk stage III melanoma. About 1,000 participants received either pembrolizumab or a placebo for up to a year. The main goal was to see if…

This phase II trial is testing whether a precise, high-dose radiation treatment called stereotactic radiosurgery can control melanoma that has spread to more than three spots in the brain. The study includes 49 patients and also checks whether this approach helps preserve memory …

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-phase trial tests a new three-drug combination for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The drugs are XL888 (an HSP90 inhibitor), vemurafenib, and cobimetinib. The main goal is to find the safest dose of XL888 when given with th…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This early-phase trial tests a new treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and then given back along with a drug called ANV419 to hel…

This early-stage trial is testing a genetically modified herpes virus called RP3, alone or combined with the immunotherapy drug nivolumab, in 123 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best…

This early-phase study tests a genetically modified herpes virus (RP2) in 36 adults with advanced solid tumors that have not responded to standard treatments. The virus is designed to infect and destroy cancer cells while also stimulating the immune system. Some participants also…

This study tests a new two-drug combination (naporafenib + trametinib) in people with advanced NRAS-mutant melanoma that has already been treated. The goal is to see if the combo works better than standard treatments at slowing cancer growth and extending life. About 78 adults wi…

This pilot study tests whether combining a targeted drug (mogamulizumab) with ultraviolet light therapy (phototherapy) can better control early-stage mycosis fungoides, a type of skin lymphoma. Twenty adults with stage IA-IIA disease will receive the drug for 8 cycles and add pho…

This phase II trial is testing whether giving the immunotherapy drug cemiplimab before surgery can help shrink tumors in people with stage II to IV head and neck skin cancer that can be removed. The study enrolled 44 participants and aims to see how many respond to the drug. If i…

This early-stage trial tests whether giving a patient's own lab-grown tumor-fighting immune cells (Lifileucel) together with the immunotherapy drug pembrolizumab can safely shrink advanced melanoma. Only 2 people with stage IIIB-D or IV melanoma took part. The goal is to see if t…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This study tests a new drug called INCB099280 in 63 adults with advanced squamous cell skin cancer that cannot be removed by surgery or radiation. The main goals are to see if the drug shrinks tumors and to check its safety. Participants take the drug and are monitored for side e…

This study tests whether a device called Sonablate can safely use high-intensity focused ultrasound (HIFU) to treat vein problems like varicose veins, leg ulcers, and certain birth defects. About 30 adults with these conditions will receive the treatment, which does not involve c…

This study tests a new drug combination (pembrolizumab plus berahyaluronidase alfa) given as a shot under the skin for Japanese patients with advanced squamous cell skin cancer that has spread or cannot be removed by surgery. The main goal is to see if the treatment can shrink tu…

This study looks at how well and how safely a combination of two cancer drugs, dabrafenib and trametinib, works when given after surgery to Chinese patients with stage III melanoma that has a specific gene change (BRAF V600). The goal is to see if the drugs help delay the cancer'…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This Phase 2 trial tests a genetically modified herpes virus (RP1) alone or with the immunotherapy drug nivolumab in people with advanced solid tumors, including melanoma, non-small cell lung cancer, and certain skin cancers. The study aims to see if the combination is safe and c…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests a combination of three drugs—niraparib, temozolomide, and atezolizumab—in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the best dose and see if the combination works better than atezolizumab alone as maintenance…

This early-stage trial tests a drug called PH-762, injected directly into skin tumors, for people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Participants receive four weekly injections into one tumor, then have it surgically removed about two weeks later. T…

This study tested two targeted drugs, dabrafenib and trametinib, given before and after surgery in 58 people with stage III melanoma that has a BRAF gene mutation. The goal was to shrink tumors before surgery and kill any remaining cancer cells afterward. The approach aims to imp…

This study tests whether adding fianlimab to the immunotherapy cemiplimab works better than cemiplimab alone for people with high-risk, removable melanoma. About 151 participants will receive the drugs before surgery, then continue after. The goal is to see if the combination des…

This early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…

This study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…

This early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …

This study tests giving two immunotherapy drugs (relatlimab and nivolumab) before surgery to people with high-risk stage II melanoma. The goal is to see if this combination can shrink or eliminate the tumor before it is removed. Twenty adults with residual disease after biopsy ar…

This early-phase study tested a new way of giving three drugs (encorafenib, binimetinib, and nivolumab) to people with advanced BRAF-mutant melanoma. Instead of taking the drugs every day, participants followed an on/off schedule to see if it could control the cancer while reduci…

This Phase 2 trial tests a new drug called purinostat mesylate in 50 people with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The drug is given by IV four times per 21-day cycle for up to 96 weeks. The main goal is to see if it can shrink tumors…

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This study tests an experimental drug called JSKN003 in Chinese adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose, and then expanding to see how well the drug shrinks tumors. About 725 parti…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This early-stage study tests a new drug called GS-4528, given alone or with another cancer drug (anti-PD-1), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 182 participants will…

This phase 2 trial is testing whether one year of pembrolizumab (an immunotherapy drug) works as well as the standard two-year course for people with advanced melanoma that cannot be surgically removed. The study involves 29 participants in Brazil's public health system and measu…

This early-stage study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Participants receive the drug until their disease gets worse or …

This study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27…

This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…

This early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…

This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…

This study tests giving the chemotherapy drug paclitaxel before and during radiation therapy for people with cutaneous angiosarcoma, a rare and aggressive skin cancer. The goal is to shrink the tumor before surgery and improve how long patients live without the cancer coming back…

This study tests a drug called brentuximab vedotin in 79 people with rare skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis) that have a marker called CD30. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 wee…

This early-phase trial is testing whether combining two drugs—pembrolizumab (Keytruda) and ibrutinib (Imbruvica)—can safely treat advanced melanoma that cannot be removed by surgery. Pembrolizumab helps the immune system fight cancer, while ibrutinib blocks enzymes that help canc…

This early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…

This study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…

This study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main…

This study tests a new proton therapy device, PROTEUS PLUS, in 47 adults with solid tumors. The goal is to see if it safely controls tumor growth. Participants receive targeted radiation, and researchers track side effects and disease response over time.

This early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This Phase 3 trial tests whether a gel called Ameluz® combined with a special red light can effectively treat superficial basal cell carcinoma, a common skin cancer. About 187 adults with at least one lesion are enrolled. The main goal is to see if the treated skin cancer clears …

This phase 2 trial tests a new drug called botensilimab, alone or with another drug balstilimab, in 150 people with advanced melanoma that stopped responding to prior immunotherapy. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Researchers will …

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to other treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 parti…

This early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check sa…

This early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a…

This early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the…

This study tests whether combining two drugs—pembrolizumab (Keytruda), which helps the immune system fight cancer, and romidepsin (Istodax), which blocks cancer cell growth—can safely treat peripheral T-cell lymphoma that has returned or not responded to prior therapy. The trial …

This phase 2 trial tests whether adding the drug tocilizumab to a standard transplant regimen can prevent graft failure and graft-versus-host disease in people with blood cancers receiving a special type of bone marrow transplant. The study involves 21 participants and aims to re…

This study tests a cream made from methylene blue, a common dye, on people with advanced basal cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. Twenty adults will apply the cream to their tumors every two days for one month. Researchers wil…

This trial is testing a new proton beam therapy device called PROTEUS® PLUS for treating solid tumors in adults. 47 participants will receive radiation from this machine to see if it is safe and effective at controlling tumors. The goal is to gather data for product registration …

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This study tests whether a special blue dye gel (methylene blue) can safely shrink skin cancer tumors and help wounds heal in people who cannot have surgery or radiation. About 20 adults with advanced squamous cell carcinoma will apply the gel every two days for a month, followed…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This early-phase study tests a personalized vaccine (NeoVax) made from a patient's own tumor mutations, given alongside two immunotherapy drugs (nivolumab and ipilimumab) for advanced melanoma that cannot be surgically removed. The main goal is to check safety and find the right …

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This early-phase trial tests a new drug that targets a specific gene (EphA2) to slow tumor growth in people with advanced solid tumors that have spread or returned. About 49 participants will receive the drug to find the safest dose and check for side effects. The goal is to cont…

This early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…

This study tests an experimental drug called RP1 that is injected directly into skin cancer tumors. The goal is to see if it can shrink or eliminate the cancer before surgery. Up to 12 adults with a type of skin cancer called cutaneous squamous cell carcinoma will take part. The …

This early-stage trial tests a new drug called DM919, alone or with pembrolizumab, in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe and effective dose and see if it can shrink tumors. Participants receive the drug by …

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This study tests a two-drug combination (tucatinib and trastuzumab) in people with advanced solid tumors that have HER2 alterations. The goal is to see if the treatment can shrink or control tumors. About 217 participants with various cancers (like lung, uterine, or bile duct) wi…

This early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…

This study was designed to test whether adding an experimental drug called TTI-101 to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with head and neck cancer that has returned or spread. The trial was withdrawn before enrolling any participants, so n…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow cancer growth. About 112 participants …

This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…

This study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…

This study tests a drug called larotrectinib in children and young adults (up to age 30) with certain cancers that have a specific genetic change called a TRK fusion. The goal is to see if the drug can shrink solid tumors or control leukemia that has returned. The drug works by b…

This phase 2 trial is testing whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from coming back after surgery compared to pembrolizumab alone. The study involves 267 people with high-risk melanoma th…

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

This study tests a new oral drug called C019199 combined with an immunotherapy drug, sintilimab, in people with advanced solid tumors that no longer respond to standard treatments. The trial involves 155 participants and aims to check safety, find the right dose, and see if the c…

This early-phase trial tests a personalized vaccine made from a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given along with chemotherapy and two immunotherapy drugs. The study includes 9 adults with advanced s…

This early-phase study tests a new drug called BR115 in 120 people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the right dose. Participants receive the drug weekly after an initial two doses, and the study moni…

This study tests a new drug called MHB039A, a bispecific antibody, in 196 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective. Participants receive the drug and are monitored for side effects and t…

This program provides expanded access to cemiplimab, an immunotherapy drug, for patients with certain solid tumors including non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. The goal is to make the treatment available to those who may not h…

This early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study aims to create a diagnostic test that can tell the difference between precancerous skin lesions (actinic keratoses) that will turn into skin cancer and those that will go away on their own. Researchers will study tissue samples from 140 patients with skin cancer and pr…

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This study tests a new dye, called cRGDY-PEG-Cy5.5-C dots, to help surgeons see cancer in lymph nodes during head and neck melanoma surgery. About 67 people will receive the dye injection around their tumor before or during surgery. The dye is not a treatment, but may improve how…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study tests whether adding a special stain called PRAME to standard tissue analysis helps surgeons remove early-stage melanoma more accurately. About 36 adults with stage 0 to IIc melanoma will have slow Mohs surgery, and their tissue will be checked both with and without PR…

This study tests a special camera that uses light and sound to take 3D pictures of skin cancer. The goal is to see how deep and wide a tumor is before surgery. About 200 people with suspected skin cancer will take part. The images will be compared to standard lab results to see i…

This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdr…

This study is testing a gene signature (the Merlin Assay) to see if it can accurately predict whether melanoma has spread to nearby lymph nodes. Researchers are enrolling 1,820 newly diagnosed melanoma patients who are scheduled for a sentinel lymph node biopsy. The goal is to de…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This study tests whether special lights and cameras can help find early signs of mouth cancer in people at high risk. About 338 participants with precancerous spots or conditions like Fanconi anemia will have their mouths examined with fluorescence imaging, which makes abnormal c…

This study compares an artificial intelligence (AI) model to dermatologists and other doctors in diagnosing skin lesions from photos. Researchers will show the same set of skin lesion images to the AI and to doctors, then compare their diagnoses to the actual diagnosis from a bio…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study is developing an artificial intelligence app to detect squamous cell carcinoma (a type of skin cancer) in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic blistering condition. Twenty adults with RDEB and a history of skin cancer will submi…

This study is testing a new, non-invasive camera that takes detailed images of skin lesions to see if it can detect skin cancer without needing a biopsy. Researchers are collecting images from nearly 1,900 people with skin lesions and comparing them to standard biopsy results. Th…

This study tests a special microscope that lets doctors check if all cancer cells have been removed during surgery for common skin cancers. About 42 adults with head, neck, or skin cancer will take part. The goal is to see if this quick method is as accurate as the standard lab t…

This study planned to use online tools like ads and social media to encourage safer sun habits and reduce skin cancer risk. It was designed for men aged 18-65 who use Facebook and are interested in LGBT topics. However, the study was withdrawn before any participants were enrolle…

This study tests whether atorvastatin, a widely used cholesterol medication, can prevent melanoma from returning or spreading in people who have had high-risk melanoma surgically removed. About 150 adults with stage IIA, IIB, or IIIA melanoma will receive either atorvastatin or a…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This phase 2 study tests whether the experimental drug bezuclastinib can reduce symptoms like itching, flushing, and fatigue in people with nonadvanced systemic mastocytosis, a rare condition where too many mast cells cause chronic discomfort. About 237 adults whose symptoms are …

This study tests four different numbing medicines (lidocaine, bupivacaine, chlorprocaine, and mepivacaine) to see which one causes the least pain when re-injected during Mohs skin cancer surgery. About 400 adults having Mohs surgery will rate their pain on a 1-10 scale. The goal …

This study compares a new non-opioid drug, suzetrigine, to the standard opioid painkiller hydrocodone/acetaminophen for pain after Mohs skin cancer surgery. Researchers want to see if suzetrigine can control pain just as well while reducing the need for opioids. The trial involve…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This early study tests whether short-term fasting (eating less than 200 calories per day for 3 days) before standard immunotherapy is safe and doable for people with advanced or metastatic skin cancer. Ten participants will receive their usual PD-1/PD-L1 inhibitor drugs along wit…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study compares two treatments for actinic keratosis, rough skin spots caused by sun exposure. About 73 adults with at least 10 spots on their head, neck, or limbs will receive both cryotherapy (freezing) and a 5-FU cream on different body areas. Researchers will track which …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study looks at whether teaching stem cell transplant survivors and their primary care doctors about skin cancer screening can lead to earlier detection. Participants receive educational materials and some doctors get a dermatoscope (a magnifying lens). The goal is to see if …

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This study follows 35 people with Merkel cell carcinoma, a rare and aggressive skin cancer, to see if two blood markers (T-antigen antibodies and miR-375) can detect when the cancer comes back. Currently, follow-up relies on physical exams and scans, which may miss early recurren…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study aims to understand how inflammation works in the skin and how certain anti-inflammatory drugs (biologics) affect it. Researchers will create small suction blisters on the skin of healthy volunteers and people with skin conditions, then analyze the fluid and cells. The …

This study looks at blood samples from 20 adults with melanoma or other skin cancers to see if certain markers in the blood can predict how well treatment works or how long someone lives. Researchers will compare these markers to standard measures like tumor response and survival…

This study aimed to compare a virtual voice agent with a human agent for teaching cancer patients how to use remote monitoring devices at home. Patients with lung cancer would have been randomly assigned to get instructions from either the virtual agent or a human over the phone.…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study is looking at whether a blood test that detects circulating tumor DNA (ctDNA) can help predict if melanoma will come back or spread. Researchers are following 176 adult melanoma patients and comparing ctDNA levels with standard clinical and lab results. The goal is to …

This study looks at whether Facebook groups can help young people diagnosed with melanoma (ages 18-39) and their close relatives do more skin exams and sun protection. About 1,160 participants will join either a melanoma-focused Facebook group or a healthy lifestyle Facebook grou…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study is testing a painless, sticker-like skin test in 100 children and teens with suspicious moles. The test looks for certain genetic markers (PRAME and LINC) to see if they match the results from a standard biopsy. The goal is to learn if this noninvasive method can help …

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study looks at whether extra MRIs and blood tests can help doctors predict how head and neck tumors change during radiation therapy. Up to 100 people (80 patients and 20 healthy volunteers) will take part. The goal is to learn more about tumor growth and response, not to tes…

This study looks at how a single dose of antibiotics given before melanoma surgery changes the bacteria in your gut. Researchers want to see if these changes affect how well the body responds to surgery and cancer treatment. The study involves 20 adults with early-stage melanoma …

This early-phase study tests a tiny implantable device that delivers very small amounts of several approved cancer drugs directly into skin cancer tumors. The goal is to see if the device can safely and effectively identify which drug triggers the most cancer cell death in that s…

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study follows 500 children and young adults who received gene therapy for cancer as part of earlier trials. Researchers will monitor them for up to 15 years to detect any delayed side effects. Participants have blood tests and health check-ups at regular intervals. No new tr…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study asks 3000 people who had skin cancer surgery to fill out a one-time online survey about how they feel about their appearance, scars, and quality of life. The goal is to learn what matters most to patients after surgery. No new treatment or medication is being tested.

This study follows 450 infants and their families from birth to age 12 to learn how a child's biology and home environment work together to shape eating habits and growth. Researchers collect samples, measurements, and surveys at regular visits. The goal is to understand what inf…

This study analyzes tumor and blood samples from 763 people with bone cancer (osteosarcoma) to understand why some tumors resist chemotherapy. Researchers will test how cancer cells respond to drugs in the lab and look for genetic clues. The goal is to learn more about treatment …

This pilot study looks at how daily use of CLn Body Wash (a mild bleach solution) affects the bacteria on skin lesions in people with mycosis fungoides, a type of cutaneous T cell lymphoma. The main goal is to see if the wash reduces harmful Staphylococcus aureus bacteria. The st…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study checks if a blood test can find tiny bits of tumor DNA in people with melanoma before their surgery. About 296 adults with suspected skin cancer will give a blood sample before the tumor is removed. The goal is to see if this test can help doctors better understand a p…

This study follows 50 adults in the UK with advanced BRAF V600 mutation-positive melanoma who are starting treatment with encorafenib and binimetinib. Instead of a controlled trial, it observes how these drugs work in real-world settings, focusing on patients' quality of life ove…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study tests a computer model that uses deep learning to analyze tissue samples from 300 people with a common skin cancer called squamous cell carcinoma. The goal is to see if the model can predict whether the cancer will spread to other parts of the body. No new drugs or tre…

This small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study takes a small piece of a patient's cancer and grows it in special mice. Doctors then test many different drugs on the mouse tumor to see which ones work best. The results are shared with the patient's oncologist, who decides if and how to use the information. The goal …

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …

This study looks at how electrochemotherapy—using electric pulses to help chemotherapy enter tumor cells—changes the immune environment of melanoma skin tumors. Researchers want to see if it can turn 'cold' tumors (which don't respond well to immunotherapy) into 'hot' ones. Ten a…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…

This study invites 2,900 adults who had radiotherapy for non-melanoma skin cancer on the head or neck between 2020 and 2024 to a follow-up visit at least two years later. Participants will fill out a questionnaire about how the treated area looks and have their skin examined. The…

This study aimed to see if losing tiny, fine hairs (vellus hairs) on the eyelid could be a sign of skin cancer. Researchers planned to check patients before a biopsy and compare hair loss with the biopsy result. The study was withdrawn before it started, so no data was collected.

This study aims to find the best MRI settings for the MR-linac, a machine that combines MRI and radiation therapy. Researchers will test different scan parameters in cancer patients and healthy volunteers to get clearer, more accurate images. The goal is to improve radiation ther…

This study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were…

This study aims to understand what parents go through when their child is born with a large or giant congenital melanocytic nevus (a type of birthmark). Researchers will interview 30 parents in France to learn about their experiences and find ways to better support them. The stud…

This study follows 10 children in the Netherlands who received ipilimumab for advanced melanoma that had spread or could not be removed. Researchers are looking at long-term side effects and patient characteristics. The goal is to understand how safe the drug is over time in youn…